Evidence map›Paper›PMID 30368547›Full record

ReviewActa neuropathologica2019

C9orf72-FTD/ALS pathogenesis: evidence from human neuropathological studies.

Sarat C Vatsavayai, Alissa L Nana, Jennifer S Yokoyama, William W Seeley

Open access · greenAbstract readReview
In one paragraph

Review in Acta neuropathologica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
7.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 84 citations in OpenAlex.

  1. Review
  2. Intrathecal (GActa neuropathologica communications · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Reversal ofProceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  15. Frontiers in neuroscience · 2024
    Article
  16. GActa neuropathologica · 2023
    Article
  17. Review
  18. Article
  19. Radiogenomics ofThe Journal of neuroscience : the official journal of the Society for Neuroscience · 2023
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Sarat C VatsavayaiMemory and Aging Center, Department of Neurology, University of California, San Francisco, USA.
Alissa L NanaMemory and Aging Center, Department of Neurology, University of California, San Francisco, USA.
Jennifer S YokoyamaMemory and Aging Center, Department of Neurology, University of California, San Francisco, USA.
William W SeeleyMemory and Aging Center, Department of Neurology, University of California, San Francisco, USA. bill.seeley@ucsf.edu.
University of California, San Francisco · US

Funding

TDP-43 Loss-of-Function: Biology to BiomarkersP01AG019724 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Jennifer Merrilees · 2002 to 2026
$67.2M
PrPSc SPECIFIC INTERACTION WITH NOVEL PrP-Fc FUSION PROTEINSP50AG023501 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MILLER, BRUCE L · 2004 to 2018
$27.1M
Deep Pathological Phenotyping in Frontotemporal Dementia and Motor Neuron Disease.R01NS104437 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SEELEY, WILLIAM W · 2018 to 2022
$4.3M
Selective Vulnerability in Frontotemporal DementiaR01AG033017 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SEELEY, WILLIAM W · 2009 to 2013
$2.5M
RNA signatures of frontotemporal dementia and ALS due to C9ORF72 expansionK01AG049152 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI YOKOYAMA, JENNIFER S · 2015 to 2019
$648k
NIA NIH HHS K01 AG049152NIA NIH HHS P01 AG019724NIA NIH HHS P50 AG023501NIA NIH HHS R01 AG033017NINDS NIH HHS R01 NS104437
6 · The paper itself

Abstract

What are the most important and treatable pathogenic mechanisms in C9orf72-FTD/ALS? Model-based efforts to address this question are forging ahead at a blistering pace, often with conflicting results. But what does the human neuropathological literature reveal? Here, we provide a critical review of the human studies to date, seeking to highlight key gaps or uncertainties in our knowledge. First, we engage the C9orf72-specific mechanisms, including C9orf72 haploinsufficiency, repeat RNA foci, and dipeptide repeat protein inclusions. We then turn to some of the most prominent C9orf72-associated features, such as TDP-43 loss-of-function, TDP-43 aggregation, and nuclear transport defects. Finally, we review potential disease-modifying epigenetic and genetic factors and the natural history of the disease across the lifespan. Throughout, we emphasize the importance of anatomical precision when studying how candidate mechanisms relate to neuronal, regional, and behavioral findings. We further highlight methodological approaches that may help address lingering knowledge gaps and uncertainties, as well as other logical next steps for the field. We conclude that anatomically oriented human neuropathological studies have a critical role to play in guiding this fast-moving field toward effective new therapies.

Indexed as

Amyotrophic Lateral SclerosisAnimalsC9orf72 ProteinDNA-Binding ProteinsDNA Repeat ExpansionFrontotemporal DementiaHumansInclusion BodiesC9orf72 ProteinDNA-Binding ProteinsAmyotrophic lateral sclerosis (ALS)C9orf72Dipeptide repeat proteinsFrontotemporal dementia (FTD)RNA fociTAR DNA binding protein of 43 kDa (TDP-43)

Identifiers

PMID30368547
PMCPMC6546170
OpenAlexW2898382435

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.